Sumitomo Pharma Reports Strong Q1 Revenue Growth

Sumitomo Dainippon Pharma Co (JP:4506) has released an update.

Sumitomo Dainippon Pharma reports a promising start to the fiscal year ending March 31, 2025, with a 19.8% increase in revenue for the first quarter. Despite a challenging previous year, the company shows a turnaround with positive net profits attributable to owners of the parent. The financial position remains solid with an increase in total equity attributable to owners of the parent and a higher equity ratio.

For further insights into JP:4506 stock, check out TipRanks’ Stock Analysis page.